Biktarvy (bictegravir) is a small molecule pharmaceutical. Bictegravir was first approved as Biktarvy on 2018-02-07. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Biktarvy's patents are valid until 2036-11-08 (FDA).
|Drug Class||Antivirals: integrase inhibitors|